Noninvasive assessment of liver structural changes in case of diffuse liver diseases

Main Article Content

V.I. Didenko
I.S. Konenko
V.B. Yagmur
D.V. Orlovskyi
N.P. Dementii
O.P. Petishko


Background. The most important factors affecting the prognosis, tactics and results of the treatment of chronic diffuse liver diseases, comprising non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis associated with virus C (HCV), include the progression rate of fibrotic liver transformation and the fibrous tissue area. The fibrosis extent is a predictor of portal hypertension and such lethal complications as bleeding from esophagus varicose veins, acute liver failure and hepatocellular carcinoma. Materials and methods. The investigation involved 66 patients with chronic diffuse liver diseases. All the patients were divided into two groups and three subgroups. Group I consisted of patients with HCV and cirrhosis associated with hepatitis C virus; group II included patients with NAFLD. Depending on the severity of fibrosis, patients in each group were subdivided into three subgroups: no fibrosis (F0), moderate fibrosis (FI + FII), and marked fibrosis (FIII + FIV). Viral etiology of the disease was confirmed by the enzyme immunoassay analysis and PCR diagnostics. Group I consisted of 24 (57.1 %) men and 18 (42.9 %) women; the average age of patients was (45.8 ± 2.2) years. The diagnosis of NAFLD was confirmed by the results of objective examination (the presence of overweight, visceral distribution of adipose tissue), detection of insulin resistance and hyperlipidemia. Group II consisted of 8 men (33.3 %), 16 women (66.7 %); the average age was (47.3 ± 3.1) years. In all the patients the diagnosis was morphologically confirmed. The ultrasound examination of the liver in B-mode was performed, as well as shear wave elastography (SWE). Results. In 13 (19.7 %) cases (7 patients with HCV and 6 patients with NAFLD), fibrous changes of the liver were absent. 43.9 % of patients (19 patients with HCV and 10 patients with NAFLD) were diagnosed with a moderate stage of liver fibrosis, which coincided with stages 1 and 2 of fibrosis on the METAVIR scale. In 36.4 % of cases (16 patients with HCV and 8 patients with NAFLD), the stage of marked liver fibrosis was diagnosed, which coincided with stages 3 and 4 of fibrosis on the METAVIR scale. According to the ROC analysis, the SWE threshold value above which a moderate stage of HCV liver fibrosis was diagnosed proved to be 6.63 kPa (with the sensitivity of 94.7 % and the specificity of 85.7 %). In the assessment of marked fibrosis it was more than 8.81 kPa (with sensitivity of 93.7 % and specificity of 84.2 %). For NAFLD, the threshold value for moderate fibrosis was 5.56 kPa (AUC = 0.867 (95% CI 0.606 to 0.982; p < 0.001)), for marked fibrosis — more than 7.87 kPa (with the sensitivity of 87.5 % and specificity of 90.0 %). Conclusions. According to SWE results, a moderate fibrosis in patients with HCV corresponded to the value of 6.63 kPa and to 5.56 kPa for NAFLD; a marked fibrosis was diagnosed at values higher than 8.81 and 7.87 kPa for HCV and NAFLD, respectively. The SWE method has high sensitivity and specificity for staging of liver fibrosis in patients with HCV and NAFLD and may be recommended for the use in clinical practice. Introduction of SWE with the defined threshold values for liver parenchyma stiffness allows optimizing noninvasive diagnosis of fibrotic liver changes in patients with HCV and NAFLD.

Article Details

How to Cite
Didenko, V., Konenko, I., Yagmur, V., Orlovskyi, D., Dementii, N., & Petishko, O. (2019). Noninvasive assessment of liver structural changes in case of diffuse liver diseases. GASTROENTEROLOGY, 53(4), 230–238.
Original Researches


Vovk EI. Nealkogol'naia zhirovaia bolezn' pecheni: rukovodstvo dlia prakticheskikh vrachei [Non-alcoholic fatty liver disease: a guide for practitioners]. Moscow: Eksmo; 2016. 160 p. (in Russian).

Wang QB, Zhu H, Liu HL, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a meta-analysis. Hepatology. 2012 Jul;56(1):239-47. doi: 10.1002/hep.25610.

Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013 Mar;58(3):593-608. doi: 10.1016/j.jhep.2012.12.005.

Sapronova NG, Voloshin VV, Lukash YuV, Kantsurova MR, Manchenko EV, Kantsurov RN. Features of morphological study of patients with intrahepatic portal hypertension. Success of modern science and education. 2016;6(10):84-89. (in Russian).

Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002 Oct;97(10):2614-8. doi: 10.1111/j.1572-0241.2002.06038.x.

Van Beers BE, Daire JL, Garteiser P. New imaging techniques for liver diseases. J Hepatol. 2015 Mar;62(3):690-700. doi: 10.1016/j.jhep.2014.10.014.

Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012 May;142(6):1293-1302.e4. doi: 10.1053/j.gastro.2012.02.017.

Dewall RJ. Ultrasound elastography: principles, techniques, and clinical applications. Crit Rev Biomed Eng. 2013;41(1):1-19.

Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008 Apr;134(4):960-74. doi: 10.1053/j.gastro.2008.01.034.

You SC, Kim KJ, Kim SU, et al. Factors associated with significant liver fibrosis assessed using transient elastography in general population. World J Gastroenterol. 2015 Jan 28;21(4):1158-66. doi: 10.3748/wjg.v21.i4.1158.

Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am. 2011 Sep;40(3):507-21. doi: 10.1016/j.gtc.2011.06.010.

Ronot M, Lambert S, Wagner M, et al. Viscoelastic parameters for quantifying liver fibrosis: three-dimensional multifrequency MR elastography study on thin liver rat slices. PLoS One. 2014 Apr 10;9(4):e94679. doi: 10.1371/journal.pone.0094679.

Merchante N, Rivero-JuaÂrez A, TeÂllez F, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology. 2012 Jul;56(1):228-38. doi: 10.1002/hep.25616.

Oshmyanska NYu, Arzhanova GYu, Halenko OP. New methods of morphological analysis to evaluate progression of fibrosis in chronic hepatitis C. Modern gastroenterology. 2014;(78):16-23. (in Ukrainian).

Khalafian AA. Sovremennye statisticheskie metody meditsinskikh issledovanii [Modern statistical methods of medical research]. 3rd ed. Moscow: Lenand; 2014. 320 p. (in Russian).

Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017 Dec;67(6):1265-1273. doi: 10.1016/j.jhep.2017.07.027.

Shen J, Chan HL, Wong GL, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012 Jun;56(6):1363-70. doi: 10.1016/j.jhep.2011.12.025.

Yoneda M, Suzuki K, Kato S, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010 Aug;256(2):640-7. doi: 10.1148/radiol.10091662.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>